VISIT CURETODAY.COM   |    SIGN UP FOR THIS AND OTHER CANCER UPDATES

FEATURE

New Data Supports Tykerb Plus Femara for Metastatic Breast Cancer
By Beverly A. Caley

The combination of Tykerb (lapatinib) and Femara (letrozole) may offer a first-line oral treatment approach for postmenopausal women with hormone receptor-positive, HER2-positive metastatic disease deemed suitable for endocrine therapy... [MORE]

DAILY BLOGS

	>> Debu Tripathy, MD EDITOR-IN-CHIEF, CURE MAGAZINE The planners of the San Antonio Breast Cancer Symposium have a knack for selecting certain speakers and topics that are very timely—about one third of the program is made of up these planned sessions while the rest are abstracts that are submitted and reviewed... [MORE]
	>> Susan McClure VICE PRESIDENT & PUBLISHER, CURE MAGAZINE A gentleman came to our exhibit yesterday to tell us how important CURE had been to him when he was undergoing treatment for breast cancer. With tears in his eyes, he told several of my colleagues that our magazine offered him information and support... [MORE]

BRIEFS

• Data Confirms Zometa Reduces Bone Loss and Recurrence Risk: Zometa (zoledronic acid) is commonly used to combat bone loss caused by aromatase inhibitors, a type of hormonal therapy. Zometa is a bisphosphonate, which works by attaching to the surface of bone tissue and blocking natural bone breakdown... [MORE]

• New Agents Effectively Target HER2-Positive Cancers: Herceptin (trastuzumab) and Tykerb (lapatinib), two drugs approved for HER2-positive breast cancer, have greatly improved outcomes for patients, but researchers are now looking for new options to target HER2—a needed approach given that some cancers don’t respond while others develop resistance to the drugs... [MORE]

• Herceptin Before Surgery Highly Effective in Locally Advanced Breast Cancer: Adding Herceptin (trastuzumab) to chemotherapy before surgery prolongs survival without recurrence in HER2-positive locally advanced breast cancer, according to data from the phase III NOAH trial... [MORE]

• Phase III Trial Planned for RAD001 with Herceptin-Chemo Combo: Investigational agent RAD001 (everolimus) made news recently for its activity in kidney cancer. But now two early phase I trials have also shown the drug may have benefit in breast cancer... [MORE]

SURVIVOR STORY

Full-Time Advocate: Bringing SABCS Cutting-Edge Information Back Home
For Joan Venticinque, 56, breast cancer advocacy is a full-time job, but she tries to fit some graphic design work in her week to make a living. Venticinque, a two-time breast cancer survivor, serves as a volunteer patient navigator for Stanford University Comprehensive Cancer Center in Stanford, California. In addition, she volunteers at Breast Cancer Connections in Palo Alto, one of the oldest breast cancer support organizations in the country... [MORE]